ArticleFrontiers in veterinary science2026
Bleomycin-based electrochemotherapy for recurrent oral CD8-positive epitheliotropic T-cell lymphoma in a dog with durable local control and necrotic regional lymph node changes: a case report.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral epitheliotropic T-cell lymphoma (ETCL) is an uncommon form of canine cutaneous lymphoma involving the oral mucosa and mucocutaneous junctions. Information regarding optimal treatment strategies and prognosis is limited. Electrochemotherapy (ECT) has demonstrated efficacy against various cutaneous and subcutaneous tumors in dogs and cats; however, reports describing its use for canine oral ETCL are scarce. Case description: A 13-year-old male Beagle presented with multiple nodular lesions involving the right maxillary gingiva, buccal mucosa, and mandibular gingiva. Histopathology and immunohistochemistry confirmed CD8-positive epitheliotropic T-cell lymphoma, with more than 90% of neoplastic cells expressing CD3 and CD8. Initial treatment with oclacitinib resulted in a reduction in the size and number of the oral lesions; however, disease progression was observed after 149 days. Bleomycin-based electrochemotherapy (BLM-ECT) was subsequently performed using intravenous bleomycin (20 mg/m Conclusion: BLM-ECT provided prolonged local disease control in a dog with recurrent multifocal oral CD8-positive ETCL that had progressed despite oclacitinib treatment. Unusual necrotic changes also developed in regional lymph nodes. The etiology of these changes remained undetermined, and a causal relationship with ECT could not be established. Investigation of pathological and immunological changes following ECT is warranted. BLM-ECT may represent a feasible and repeatable local treatment option for selected dogs with oral ETCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.